Low dose fluorometholone stops endothelial rejection after PKP

Article

Using 0.1% fluorometholone after penetrating keratoplasty (PKP) significantly reduces the chances of endothelial rejection.

Using 0.1% fluorometholone after penetrating keratoplasty (PKP) significantly reduces the chances of endothelial rejection, claims a study in Ophthalmology.

A randomized, non-blinded, clinical trial, led by Dr Jun Shimazaki, Department of Ophthalmology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan, included 42 patients who underwent PKP. Each patient had been administered topical steroid eye drops and maintained graft clarity for over one year.

The participants were randomly assigned to two groups and were assessed for 12 months. Group was administered 0.1% of fluorometholone three times daily and group 2 were not administered any steroids.

In group 1 there were 17 patients who completed the trial and in group 2 there were 15 patients. Endothelial rejection was developed in 1 patient in group 1 and 6 patients in group 2 at an average of 5.2±4.5 after PKP.

There were no differences in visual acuity, intraocular pressure, epithelial damage, tear film break-up time, cataract progression, infection, or incidence of systemic side effects between the groups.

There were no adverse effects reported when using 0.1% fluorometholone and the study suggests using low dose corticosteroids even in low-risk cases.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.